VIR

VIR is a pre-commercial, clinical-stage biopharma, so the headline P/S of 21.1x on $68.6M of license/grant revenue (down 7.6% YoY) is not a meaningful valuation anchor — the $1.45B market cap is a bet on the pipeline, not the income statement. The reality is a company losing money at scale: a -$438M net loss, a -699% operating margin, and -$392M of operating cash burn. The MD&A confirms revenue is collaboration- and grant-driven (license/collab $63.1M, grant revenue down to $2.0M), not product sales, and management explicitly expects SG&A to rise as it pushes toward commercialization. With accumulated deficit at -$1.20B and ROE -57%, this is a story stock, gradedon trial outcomes.

The balance sheet is the swing factor. Liabilities/equity is a benign 0.31x and equity is $765M, so there is no debt distress — but liquidity is the live risk. Against $392M annual cash burn, the company holds only $232M of cash and $514M of total current assets (the latter down 50.7% YoY). On that math VIR has roughly a year-and-change of runway at the current burn before it must raise capital, and shares are already creeping up (+1.7% YoY). A financing around the key 2026/27 readouts is a realistic dilution overhang that a buyer should price in.